Biohaven Ltd. (“Biohaven” or the “Company’) (BHVN) is a clinical-stage biopharmaceutical company that combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry and expertise in global clinical trials to advance novel therapies for patients. The Company’s experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia, and their research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with target indications, including epilepsy, mood disorders, Obsessive-Compulsive Disorder, Spinocerebellar Ataxia, Spinal Muscular Atrophy and pain disorders. Biohaven’s neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels, glutamate receptors, myostatin, and transient receptor potential channels.